Qiagen N.V. (NYSE:QGEN) Receives Consensus Rating of “Hold” from Analysts

Qiagen N.V. (NYSE:QGEN) has been assigned a consensus rating of “Hold” from the ten analysts that are presently covering the company, MarketBeat Ratings reports. Seven analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $49.6944.

QGEN has been the subject of a number of analyst reports. UBS Group boosted their price target on Qiagen from $48.00 to $50.00 and gave the stock a “neutral” rating in a research report on Thursday, August 7th. Cowen restated a “hold” rating on shares of Qiagen in a report on Thursday, August 7th. Wall Street Zen raised Qiagen from a “hold” rating to a “buy” rating in a research report on Saturday, November 1st. Barclays set a $53.00 price target on shares of Qiagen and gave the company an “overweight” rating in a research report on Thursday, October 2nd. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Qiagen in a research note on Tuesday.

Institutional Investors Weigh In On Qiagen

A number of hedge funds have recently bought and sold shares of QGEN. SVB Wealth LLC bought a new position in shares of Qiagen in the first quarter worth about $31,000. Danske Bank A S acquired a new stake in Qiagen in the 3rd quarter valued at approximately $36,000. Smartleaf Asset Management LLC grew its holdings in Qiagen by 1,383.3% in the 3rd quarter. Smartleaf Asset Management LLC now owns 890 shares of the company’s stock valued at $39,000 after buying an additional 830 shares during the last quarter. MAI Capital Management increased its position in Qiagen by 998.9% in the 2nd quarter. MAI Capital Management now owns 978 shares of the company’s stock worth $47,000 after buying an additional 889 shares during the period. Finally, Farther Finance Advisors LLC lifted its holdings in shares of Qiagen by 400.5% during the second quarter. Farther Finance Advisors LLC now owns 1,061 shares of the company’s stock worth $51,000 after buying an additional 849 shares during the last quarter. 70.00% of the stock is currently owned by institutional investors.

Qiagen Stock Performance

QGEN stock opened at $47.75 on Friday. The firm has a 50 day moving average of $46.29 and a two-hundred day moving average of $46.84. Qiagen has a 12 month low of $37.63 and a 12 month high of $51.88. The company has a market capitalization of $10.61 billion, a price-to-earnings ratio of 28.21, a P/E/G ratio of 2.48 and a beta of 0.64. The company has a quick ratio of 1.35, a current ratio of 1.61 and a debt-to-equity ratio of 0.25.

Qiagen (NYSE:QGEN) last released its quarterly earnings data on Thursday, November 6th. The company reported $0.61 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.03. The business had revenue of $532.58 million during the quarter, compared to analyst estimates of $525.68 million. Qiagen had a net margin of 18.30% and a return on equity of 14.77%. Qiagen’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.57 EPS. As a group, equities analysts anticipate that Qiagen will post 2.26 EPS for the current fiscal year.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.